New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Genzyme Drug Discovery & Development
Division of Sanofi
www.geltex.com
Latest From Genzyme Drug Discovery & Development
Can Big Pharma Save Biotech Investors?
All the biotech stock indices are down; record numbers of companies are selling at lower-than-cash valuations. Investors want Pharma to step up and buy, removing inventory from the market, and spreading limited investment dollars over a smaller set of opportunities. While buyers say they aren't going to radically change their strategies simply to take advantage of cheap prices, it's clear that more deals will get signed - mostly because more sellers will accept terms they once would have rejected. . In short, a hotter dealmaking climate will keep biotech healthy enough to survive as an industry, albeit a smaller one, and, perhaps, with a slightly lower ceiling on returns.
The New Polymer Drugs--They're Not Just for Delivery Anymore
Polymers have long been useful as critical components in delivering or stabilizing a variety of medicines. Now a small band of companies that includes Genzyme, Ilypsa and Midway Pharmaceuticals is going one step further: they are designing polymers that aren't just inert drug delivery vehicles, but are themselves therapeutic agents.
Neck-and-Neck in Nephrology
Nabi with PhosLo and Genzyme with Renagel now split the market for dialysis patients requiring treatment for high phosphate levels. Soon a third firm will enter the fray--the UK's Shire. Thus far, the marketing battle has been fought with nitty-gritty clinical data. But now Genzyme is raising the notion of "accumulation" to stigmatize competitors, while Nabi emphasizes the issue of cost. The competitive stakes are rising because Medicare changes in 2006 will dramatically expand the market.
Amgen Moves Beyond Proteins
Amgen's revenue stream depends largely on just two molecules. It has spent loads of money on the search for replacements, but as yet has relatively little to show for it--at least, little that's been visible to those outside the company. To enlarge its opportunity set, Amgen is moving beyond its macromolecule-only heritage. A fresh cadre of executives, many from Merck, aim to add small-molecule capabilities and leverage corporate understanding of proteins and pathway biology. Amgen is also tapping into a host of other organizations whose technologies, targets, assays and very ways of thinking promise to make the firm more competitive than it could be on its own. While some investors think Amgen is making all the right moves, others are still concerned about the company's ability to bring enough new drugs to market, fast enough, to fill in behind its blockbuster proteins.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- GelTex Pharmaceuticals Inc.
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Sanofi
- Senior Management
-
Paul J Mellet, VP, Admin. & Fin. & CFO
Timothy Noyes, VP, Mktg. & Bus. Dev.
Edmund J Sybertz, PhD, SVP, R&D - Contact Info
-
Genzyme Drug Discovery & Development
Phone: (781) 290-5888
153 Second Ave.
Waltham, MA 02154
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme Drug Discovery & Development
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice